April 2026 in “Journal of the American Academy of Dermatology” Oral 5-alpha-reductase inhibitors for hair loss don't increase heart risk.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
March 2025 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil doesn't affect blood pressure in patients taking blood pressure meds.
July 2026 in “Journal of the American Academy of Dermatology” Finasteride may lower depression risk in younger men with hair loss but increase it in older men with prostate issues.
December 2025 in “Cureus” Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
January 2026 in “Journal of the American Academy of Dermatology” 5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
March 2026 in “Journal of the American Academy of Dermatology”
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
February 2026 in “JAAD International” May 2026 in “Mendeley Data” May 2026 in “Mendeley Data” April 2026 in “Mendeley Data” January 2026 in “JAAD International” August 2025 in “Journal of the American Academy of Dermatology” 2 citations
,
May 2025 in “Archives of Dermatological Research” JAK inhibitors do not increase cancer risk in severe alopecia areata compared to traditional treatments.
Long-term, low-dose finasteride may reduce the risk of benign prostatic hyperplasia and prostate cancer.
July 2025 in “Journal of Investigative Dermatology” Systemic therapy may reduce male infertility in psoriasis patients.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
July 2024 in “Journal of Investigative Dermatology” Allergies, especially both seasonal and food, increase the risk of developing alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
4 citations
,
August 2024 in “International Journal of Impotence Research” Low testosterone increases kidney stone risk in men not on testosterone therapy.
November 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may reduce depression in people with alopecia areata.
January 2026 in “In Vivo” People with hidradenitis suppurativa have a higher risk of kidney stones.
October 2025 in “EMJ Dermatology” GLP-1RA therapy may increase the risk of hair loss.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
6 citations
,
October 2024 in “npj Digital Medicine” Long-COVID causes more health issues after COVID-19, varying by age, sex, and infection wave.
3 citations
,
July 2025 in “BIOMED natural and applied science” Drug repurposing can create safer, cheaper treatments by finding new uses for existing drugs.
1 citations
,
December 2025 in “American Journal of Clinical Dermatology” Menopause influences skin conditions, and hormone therapy should be considered in treatment.
June 2026 in “Dermatology and Therapy” GLP-1RAs, like semaglutide and tirzepatide, may cause hair loss, so patients should be informed and monitored.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.